Delineating the effect of sex hormone intake on immunity in cis and 1 2 trans women with HIV

3 Chloé Pasin^{1,2,3,*}, David Garcia Nuñez⁴, Katharina Kusejko^{1,2}, Anna Hachfeld⁵, Hélène Buvelot⁶, Matthias Cavassini⁷, Lauro Damonti^{5,8}, Christoph Fux⁹, Begoña Martinez de 4 Tejada¹⁰, Julia Notter¹¹, Alexandra Trkola², Huldrych F. Günthard^{1,2}, Karoline Aebi-5 Popp^{5,\$}, Roger D. Kouyos^{1,2,\$}, Irene A. Abela^{1,2,\$}, and the Swiss HIV Cohort Study 6 7 8

- 9 ¹ Department of Infectious Diseases and Hospital Epidemiology, University Hospital
- 10 Zurich, University of Zurich, Zurich, Switzerland.
- ² Institute of Medical Virology, University of Zurich, Zurich, Switzerland. 11
- 12 ³ Collegium Helveticum, Zurich, Switzerland.
- 13 ⁴ Center for Gender Variance, Department of Plastic, Reconstructive, Aesthetic and
- 14 Hand Surgery, University Hospital Basel, Basel, Switzerland.
- ⁵ Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland 15
- 16 ⁶ Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
- 17 ⁷ Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland
- 18 ⁸ Ente Ospedaliero Cantonale, Division of Infectious Diseases, Regional Hospital
- 19 Lugano, Lugano, Switzerland
- 20 ⁹ Department of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau,
- 21 Switzerland
- ¹⁰ Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva 22
- and Faculty of Medicine, Geneva, Switzerland 23
- 24 ¹¹ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St.
- 25 Gallen, St. Gallen, Switzerland
- 26
- 27 * Corresponding author: chloe.pasin@usz.ch
- ^{\$} These authors contributed equally. 28

29 Abstract

30 **Background:** Although sex hormones are recognized to induce immune variations, little 31 is known on the effect of exogenous sex hormone intake on immune responses in cis and 32 trans women. Here, we aimed at quantifying how sex hormone intake affects HIV-1 33 immune markers in cis women (CW) and trans women (TW) with HIV.

Methods: We considered measurements of key HIV-1 immune markers (CD4, CD8, lymphocyte counts, and CD4:CD8 ratio) from cis men (CM), CW, and TW enrolled in the Swiss HIV Cohort Study. We modeled immune markers using linear mixed-effects models with an interaction between the variables "group" (CW, TW) and "with sex hormone intake" (yes/no). We conducted serum proteomics measurements of 92 inflammation markers on samples from 31 TW before and after sex hormone intake to assess the inflammation environment.

41 Results: We included 54'141 measurements from 3'092 CW and 83 TW sampled 42 between 2015 and 2022, and 147'298 from 8'611 CM. Sex hormone intake was 43 associated with significant distinct effects on CD4 and CD4:CD8 ratio between the 44 different groups of women (p=0.0025 and 0.015). TW with sex hormone intake had 45 significantly higher CD4 counts (median = 772 (1Q-3Q=520-1'006)) than without (median 46 = 617 (1Q-3Q=426-892)). This increase was similar in magnitude to the difference in CD4 47 counts between CW and CM. None of the serum inflammation proteins showed significant 48 concentration difference before and after sex hormone intake in TW. 49 **Conclusion:** This study highlights the need to consider the potential role of sex hormone

intake in modulating the immune system among other biological and social factors,
 especially in TW in HIV.

52 Introduction

53 Sex and gender differences in the immune response have been observed in many 54 settings, and in general women mount more robust cellular and humoral immune 55 responses to infection and vaccination compared to men (1-6). These differences are 56 multifactorial and could be influenced by the immuno-modulatory effect of sex hormones 57 (7-9), with oestrogens having a stimulating effect (10) while testosterone having a 58 suppressive effect on immune function (11). Sex hormones have also shown a multilevel 59 effect on chronic infections such as HIV-1 (12), where women have displayed lower viral loads (13-15) and higher CD4+ T cell counts (16, 17) than men following seroconversion, 60 61 and higher levels of immune activation (18, 19). Women also tend to have a lower latent 62 HIV-1 reservoir size (20-22) and oestrogens were found to inhibit HIV-1 transcription (23). 63 Although sex hormones could play a role in HIV-1 acquisition risk (24), recent evidence 64 suggest that hormonal contraception does not affect the risk of HIV-1 acquisition (25-28) 65 or disease progression (29, 30). 66 However, the effect of sex hormones intake on HIV-1 immune markers dynamics has 67 been insufficiently explored. Additionally, most of the findings previously mentioned were 68 obtained by studying cis women (CW) versus cis men ("cis" referring to people whose 69 gender identify matches the one assigned at birth), or without specifying this information. 70 Trans women (TW, referring to people who were recorded male at birth but do not identify 71 with being a man) are disproportionally affected by HIV-1 (31, 32) and constitute a distinct 72 epidemiologic group compared to men having sex with men and cis women (32-34). TW 73 are still under-represented in HIV-1 research; therefore, little is known on the immune 74 effect of sex hormone intake in TW and more generally on the effect of hormonal therapy

taken by TW on HIV-1 suppression and longer-term health outcomes (35-38). Additionally,

concerns on drug-drug interactions between antiretroviral treatment (ART) and sex
 hormones might limit hormone prescription in women with HIV-1 (39, 40).

The aim of this study was to analyze sex hormone intake in CW and TW from the SHCS, and to delineate the effect of sex hormones on key HIV-1 markers in CW and TW with sex hormone intake or not. Furthermore, we aimed to characterize the potential immunomodulatory effect of sex hormones in TW by measuring inflammatory protein levels before and after sex hormone intake using a high-throughput proteomics assay.

83

84 Results

85 Study population

86 Participants from the Swiss HIV Cohort Study (SHCS) attend biannual visits during which 87 blood samples are drawn and the following laboratory measurements are realized: 88 number of leucocytes, lymphocytes, CD3+, CD4+, and CD8+ T cells (cells/µL), HIV-1 viral 89 load (copies/mL). We considered measurements realized after January 1st, 2015: from 90 that date, the SHCS data contains systematic report of most comedications using the 91 ATC codes nomenclature. We included in the analysis a total of 54'141 laboratory 92 measurements between January 2015 and September 2022 from 954 CW younger than 93 40 vears-old (CW<40), 2'365 CW between 40 and 60 years-old (CW 40-60), 573 CW 94 older than 60 years-old (CW>60), and 83 TW (Figure 1). As a comparison we also 95 considered similarly selected 147'298 laboratory measurements from 8'611 cis men.

96 As previously described (33), TW in the SHCS were more likely to be of Asian and 97 Hispano-American ethnicity compared to CW and had overall similar education levels as 98 CW (Table 1). A higher proportion of TW had ever taken sex hormones compared to CW 99 (69.9% versus 18.9%). We observed the highest CD4+ T cell, CD8+ T cell, and 100 lymphocyte counts in TW with sex hormone intake (median respectively 772 cells/ μ L, 822 101 cells/µL, and 2288 cells/µL), while the CD4:CD8 ratio was the lowest in TW without sex 102 hormone intake (median 0.80) (Table 2, Figure 2, Supplementary Figure 1, 2). CW>60 103 with sex hormone intake had the lowest proportion (0.2%) of samples with detectable viral 104 load (RNA > 50 copies/mL), and TW without sex hormone intake the highest (8.3%). Of 105 note, only a small proportions of viral load measurements in TW without sex hormone 106 intake were above 1'000 copies/mL (1.3%, Supplementary Table 1).

107

108 Diversity of sex hormone intake in women from the Swiss HIV Cohort Study

Using information contained in the ATC codes, we were able to further differentiate the type of sex hormones taken by women from the SHCS, as well as their route of administration (Table 3, Supplementary Figure 3). CW<40 mostly reported the use of systemic progestogens (35.1%) or combined oestrogens and progestogens (36.9%), in line with the use of hormonal contraception (HC). CW>60 mostly reported the use of local

114 oestrogens (63.2%) or systemic combined oestrogens and progestogens (21.1%), 115 corresponding to the use of menopause hormone therapy (MHT). In the group of CW 40-116 60, we observed more heterogeneity, with reports of HC use (systemic combined 117 oestrogens and progestogens, 38.4%, and systemic progestogens, 21.1%) but also MHT 118 (systemic and local oestrogens, respectively 17.6% and 14.5%), reflecting the potential 119 overlap of contraception with the need for managing symptoms during perimenopause. 120 Finally, TW mostly reported the use of oestrogens (53.2%) or combined oestrogens and 121 antiandrogens (32.9%). Our descriptive analysis highlighted the diversity of sex hormone 122 intake in women from the SHCS and the complexity of the data when assessing and 123 comparing different age groups.

124

Sex hormone intake is associated with distinct effects on immune markers in CW and TW with HIV

127 We assessed the effects of sex hormone intake on immune markers by using linear 128 mixed-effect models adjusted for potential confounders such as years since ART start. 129 ethnicity, intravenous drug use, education level, and age (Figure 3, Supplementary Figure 130 4). We found significantly different effects of sex hormone intake on CD4 and CD4:CD8 131 ratio between the studied groups (CW<40, CW 40-60, CW>60, and TW) (interaction 132 p^{CD4}=0.02, p^{ratio}=0.007). Interestingly, we found a significant increase of CD4 counts, 133 CD4:CD8 ratio, and lymphocyte counts associated with sex hormone intake in TW (effect 134 on the scaled outcomes = 0.19, 95% confidence interval [0.10,0.28] for CD4 counts, 0.08 135 [0.02,0.15] for CD4:CD8 ratio, and 0.15 [0.04,0.25] for lymphocytes counts). CD4 and 136 lymphocyte counts displayed high correlation in TW (Pearson r=0.78, p<0.001, 137 Supplementary Figure 5), suggesting that the increase in lymphocyte counts in TW with 138 sex hormone intake was mostly due to the observed increase in CD4 counts.

139 Chronic viral and bacterial infections and lifestyle factors such as smoking could have an 140 impact on immune markers (41-43). We conducted sensitivity analyses adjusted on 141 smoking status and co-infection with hepatitis C and/or syphilis and found consistent 142 results on the effect of sex hormones on immune markers (Supplementary Figure 6). We 143 further investigated whether changes in immune markers could be linked to viral control, 144 adherence to ART, and/or mental health problems. Interestingly, sex hormone intake was

145 significantly correlated with undetectable or suppressed viral load in both CW and TW 146 (chi square test p<0.001 for CW<40, CW>60, and TW, and p=0002 for CW 40-60, 147 Supplementary Table 1), with better self-reported adherence in CW<40 (chi square test p<0001) and CW 40-60 (chi square test p<0.001), but with more depression in CW<40 148 149 (chi square test p=0.025). When adjusting for depression, self-reported adherence, and 150 viral load, the increase of CD4 counts in TW upon sex hormone intake remained 151 significant (effect on the scaled outcome = 0.14 [0.05,0.23], Supplementary Figure 7), 152 suggesting that this increase cannot solely be explained by better adherence to treatment 153 and control of the virus.

154 We further investigated whether the effects of sex hormones on immune markers in CW 155 and TW were comparable to the differences in immune marker levels between cis men 156 and CW (Supplementary Figure 8). Interestingly, the size of the effect of sex hormones 157 on CD4 counts in TW was very similar to the difference of CD4 counts in CW (without sex hormone intake) versus cis men (CM, effect on the scaled outcome = 0.19 [0.14,0.24]). 158 159 However, the effect on CD8 counts and lymphocytes was different, suggesting that sex 160 and gender differences in immune markers cannot fully be compared to the inferred effect 161 of exogenous sex hormone intake in CW and TW.

162 Considering the diversity of sex hormones taken by the population of women in the SHCS, 163 we also investigated the effect of different type and route of hormones among the defined 164 groups (Figure 4). Among TW taking sex hormones, we found trends for lower CD4, CD8, 165 and lymphocyte counts in TW with combinations of oestrogens and antiandrogens versus TW taking oestrogens only (p^{CD4}=0.075, p^{CD8}=0.052, and p^{lymphocytes}=0.090). Among 166 167 CW<40 taking sex hormones, we observed significantly lower CD8 and lymphocyte counts and higher CD4:CD8 ratio (p^{CD8}=0.050, p^{lymphocyte}=0.015, p^{ratio}=0.004 respectively) 168 169 among those taking progestogens only versus those taking oestrogens and progestogens 170 in combination.

171

172 No evidence for inflammatory pathways activation upon sex hormone intake in TW

We further sought to identify whether sex hormone intake had an anti-inflammatory effect in TW (44). To do so, we assessed the effect of sex hormone intake on immunity in 31 TW (19 taking oestrogens only and 12 taking a combination of oestrogens and

176 antiandrogens) by undertaking a targeted proteomic analysis of individual soluble 177 inflammation-associated proteins in two sequential samples: one taken up to 2 years 178 before the start of sex hormone intake (median 176 days, 1Q-3Q = 58-240 days) and one 179 taken between 1 and 18 months after the start of sex hormone intake (median 175 days, 180 1Q-3Q = 155-225 days). Using an unsupervised hierarchical clustering strategy, we found 181 no distinct immune signature between the samples taken before and after sex hormone 182 intake (Supplementary Figure 9). After adjustment for multiple testing, we found no 183 significant differential protein concentration in TW before and after sex hormone intake 184 (Supplementary Table 2). Only two proteins displayed significant changes when 185 considering the p-value unadjusted for multiple testing, namely neurotrophin-3 (NT-3, 186 p=0.019) and STAMBP (p=0.032), for which we observed a decreased concentration 187 upon sex hormone intake (Supplementary Figure 10).

188

189 **Discussion**

We report here on the first large cohort study analyzing the impact of exogenous sex hormone intake on the immune system in women with HIV. Our study explicitly included TW in the analysis to gain insights into effects of sex hormone intake on the immune system in a population often understudied in HIV-1 research.

Although rates of MHT intake in menopausal cis women were previously reported in the SHCS (45), we were now able to extensively describe the diversity of sex hormones taken by women in the SHCS. Notably, our analysis highlighted the complexity of the menopausal transition, during which the need of HC and MHT are likely to overlap.

198 Based on a number of studies partially attributing sex and gender differences in immunity 199 to the role of sex hormones (1-5, 16), we investigated how exogenous sex hormone intake 200 affect major HIV-1 immune markers. Observed differences of sex hormone intake on 201 immune markers (CD4, CD4:CD8 ratio) in CW and TW could be due to differences in the 202 combination of hormones taken. Indeed, TW mostly reported intake of oestrogens and/or 203 antiandrogens and CW mostly reported intake of oestrogens and/or progestogens, 204 depending on their age. Additionally, within each group, we did observe significant (in 205 CW<40) or trends (in TW) of differential effects on HIV-1 markers by type of sex hormone.

206 Differences in dosing and mechanisms of actions of sex hormones on the immune system 207 in CW and TW could also explain our results and should be further investigated.

Our most robust result was the significant association between sex hormone intake and an increase in CD4 counts in TW. This increase was similar in magnitude to the difference of CD4 counts between CW (not taking sex hormones) and CM, but this similarity was not identified for the other markers (CD8, CD4:CD8 ratio, lymphocytes). In line with previous work (46-48), this highlights the complexity and variety of factors (chromosomal, hormonal, and social) playing a role in immune modulation.

214 Additionally, we explored how factors such as adherence and mental health could play a 215 role in our analyses. Indeed, it has been reported that sex hormone intake in TW can be 216 associated with lower adherence to ART, driven by concerns of drug-drug interactions 217 (38, 39, 49). However, access to gender-affirming hormone therapy in TW was also 218 shown to be associated with overall better mental health (50-52), which is known to be a 219 good predictor for adherence in people with HIV (53-56). In our analysis, we did not find 220 any association in TW between sex hormone intake and self-reported adherence to ART 221 or depression. Even after adjusting for these variables, we still found a significant increase 222 in CD4 counts with sex hormone intake in TW, suggesting that other social and biological 223 factors are potentially responsible for this increase. However, we did identify a correlation 224 between depression and HC in CW<40, in line with previous reports (57-59). Although 225 previous results showed that mental health was not associated with adherence to ART or 226 viral suppression during menopausal transition (60), more studies are needed in CW and 227 TW with HIV to investigate the interplay between sex hormone intake, mental health, and 228 immunity.

229 Using a high-throughput serum proteomics approach, we aimed at identifying the 230 inflammatory pathways potentially modulated with sex hormone intake in TW. We could 231 not identify any proteins with significant concentration change before and after sex 232 hormone intake in TW after adjusting for multiple testing. This negative result could be 233 due to our low sample size or to the timing of the sampling before and after the start of 234 sex hormone intake. Indeed, a previous report found that inflammatory markers were only 235 transiently modified in TW receiving oral oestrogens, with a return to baseline levels 236 between 2 to 6 months after the start of oestrogens intake (61). As the samples retrieved

from our biobank were obtained with a median of around 6 months after the start of sex hormone intake, we cannot exclude that this time window was not allowing us to identify transient inflammatory changes happening earlier after the start of sex hormone intake.

- 240 Although all our statistical analyses were adjusted for confounders and we conducted 241 several sensitivity analyses, this study is observational by design, and it is therefore not 242 possible to definitely conclude on the causality between sex hormone intake and increase 243 of CD4+ T cell counts in TW. Our analysis did not include longitudinal modeling of immune 244 trajectories, preventing us to draw final conclusions on the time between start of sex 245 hormone intake and potential modulations of immune markers. However, measurements 246 at more regular and specific timepoints would be required to address this question. 247 Additionally, we only observed the total number of cells, and the cohort design does not 248 include any phenotyping of cells, which is preventing us to conclude on the cell subtypes 249 with increased population with sex hormone intake.
- In conclusion, our results present new insights on the effect of exogenous sex hormone intake on the immune system of cis and trans women with HIV and highlights the need to consider the potential role of sex hormones in modulating the immune system among other biological and social factors.
- 254

255 Methods

256 Swiss HIV Cohort Study

257 The Swiss HIV Cohort Study (SHCS) is a prospective multicenter cohort study enrolling 258 people with HIV in Switzerland (62). The SHCS was approved by the local ethical 259 committees of the participating centers, and written informed consent was obtained from 260 all participants. Participants are followed-up biannually with data collection including 261 behavioral information, drug intake, gynecological exam if applicable. Blood samples are 262 systematically drawn at each visit for laboratory measurements and storage in a biobank. 263 In the main analysis, we considered laboratory measurements from samples drawn in 264 CW and TW after January 1st, 2015, when systemic report of most comedications taken 265 by SHCS participants started. Reports include (since 2015) ATC codes, drug brand, dose, 266 and route of administration for both antiretrovirals and co-medication. We excluded from 267 the analysis laboratory measurements that were sampled when participants were not on

ART, less than 3 months after the first start of ART intake, during pregnancies, and during hormone intake as subsequent treatment for bacterial vaginosis or treatment for endometriosis (as these conditions could themselves be associated with changes in immunity).

- As a comparison we also considered laboratory measurements in 147'298 samples on
- ART for at least 3 months from 8'611 cis men after January 1st, 2015.
- 274

Cis and trans women in the SHCS

- We identified 86 TW using criteria previously described (33), and 3'165 CW with at least
- one laboratory measurement after January 1st, 2015.
- 278

279 Sex hormone intake definition

280 Sex hormone intake was assessed using the following ATC codes: G02BA03 (hormonal 281 intrauterine contraceptive with progestogens), G02BB (contraceptive vaginal ring with 282 oestrogens and progestogens in combination), G03A (hormonal contraceptive for 283 systemic use), G03C (oestrogens), G03D (progestogens), G03E (androgens and female 284 sex hormone in combination), and G03F (progestogens and oestrogens in combination). 285 For each ATC code, report of the start and end of the corresponding drug are indicated. 286 Sex hormone reports for each participant were obtained by combining different sex 287 hormones when taken at the same time (Supplementary Figure 3), then classified by the 288 type (e.g., oestrogens, progestogens, oestrogens + antiandrogens) and route (e.g., 289 systemic, local) of intake. For example, a participant's report with a simultaneous intake 290 of a product with ATC code G03CA (transdermal, oestrogens) and another product with 291 ATC code G03AC (systemic, progestogens) will be classified as systemic oestrogens + 292 progestogens.

293 Measurements that were realized on blood samples drawn during the period of sex 294 hormone intake were labeled as "with sex hormone intake", others "without sex hormone 295 intake".

296

297 Smoking, depression, and adherence definition

Information on smoking, depression, and self-reported adherence to ART (obtained
 during bi-annual visits) were linked to laboratory measurements realized up to 6 months
 before the corresponding follow-up visit.

301

302 Proteomics measurements

303 We retrieved plasma samples from the SHCS biobank: we selected 31 TW for which 304 plasma samples were available both before the first reported start of sex hormone intake 305 (between one month and two years) and after it (between three months and two years). 306 with no reported interruption between the start of intake and the plasma collection. 307 Proteomics measurements were realized on the 62 retrieved samples using the Olink® 308 Target 96 technology Inflammation panel (63), which enables high-throughput, multiplex 309 immunoassays by measuring up to 92 proteins across 96 plasma samples simultaneously 310 (Olink Bioscience AB, Uppsala, Sweden). Olink® Target 96 is based on the Proximity 311 Extension Assay (PEA). Using oligonucleotide-labeled antibody probe pairs, PEA permits 312 simultaneous assessment of multiple proteins, maintaining the precision of dual epitope 313 ELISA without the loss of specificity of earlier generation multiplex assays. Signal 314 production requires both recognition of DNA barcoding from sequence-specific 315 oligonucleotides and dual recognition of correctly matched antibody pairs. The PEA assay 316 reports fold change in log₂ (Normalized Protein eXpression [NPX]) units. The 317 Inflammation panel informs on factors involved in cell differentiation and cytokine-318 mediated signaling pathways.

319

320 Statistical analysis

321 Studied outcomes (CD4+ T cell count, CD8+ T cell count, CD4:CD8 ratio, and total 322 lymphocyte count) were transformed using square-root transformation for the cell counts 323 and log transformation for the ratio, and then scaled. Each outcome was then expressed 324 using a linear mixed effect model with fixed effects for the adjustment variable and a 325 random effect for the individuals to account for repeated measurements. The linear mixed 326 effect model can be written as follows:

$$y_{ij} = \sum_{k=1}^{n} \beta_k x_{kij} + b_i + \varepsilon_{ij}$$

Where y_{ij} is the jth observation of participant i, x_k is the kth of n fixed effects (variable of adjustment) and β_k its corresponding coefficient, b_i is the participant-specific normally distributed random effect and ε_{ij} the normally distributed residual error.

331 For the fixed effect, we included a "group" variable (CW<40, CW 40-60, CW>60, TW) and 332 a variable "with sex hormone intake" (yes, no). We considered CW in different age groups 333 due to the strong correlation between the type of sex hormones used and the age of CW 334 (i.e., CW<40 mostly take hormonal contraception, CW>60 mostly take hormonal 335 replacement therapy, while the hormones taken by CW 40-60 are more heterogeneous). 336 We tested whether the sex hormone intake was associated to the outcome differentially 337 in the respective groups by estimating an interaction between the group variable and the 338 sex hormone intake variable. The reference category was CW 40-60, as this was the 339 group with the biggest sample size. We assessed the significance of the interaction term 340 using a likelihood ratio test (complete model with interaction term, reduced model without 341 interaction term). We report the effect of sex hormone intake in the different groups on 342 the scaled outcomes and p-value of the likelihood ratio test for the interaction term. To 343 control for potential confounders, we adjusted the models on the following variables: age 344 at time of sample (continuous with splines), ethnicity, education level, time since ART start (continuous with splines), use of intravenous drugs. In sensitivity analyses, we also 345 346 adjusted for depression, smoking status at time of sampling, self-reported adherence 347 (three categories: never missed, missed once a month, and missed more than once every 348 two weeks) and viral load (three categories: below 50 copies/mL, 50-1'000 copies/mL 349 and >1'000 copies/mL).

350 Given the left-censored nature of the proteomics data, the analysis was conducted in two 351 steps: we first pre-selected proteins of interest, by excluding those with a proportion of 352 censored values among the 62 samples more than 75%, and a dispersion value (standard 353 deviation divided by the mean value) less than 5%. We then tested for differences 354 between pre and post sex hormone intake samples using paired t-tests. Paired t-tests in 355 proteins with left-censored data were realized using the function cen paired from the 356 NADA2 R package. These analyses were conducted on all samples, on the subset of 357 samples in participants taking oestrogens only, and on the subset of samples in

- 358 participants taking a combination of oestrogens and anti-androgens. Multiple testing was
- 359 corrected using the FDR method.

Figure 1: Flow chart of laboratory measurements selection and repartition in the different subgroups. N corresponds to the number of samples with lab measurements, n corresponds to the number of SHCS participants (one participant can have several samples with lab measurements included in the analysis and can contribute to both the no hormone intake and hormone intake groups).

366

Figure 2: Distribution of CD4+ and CD8+ T cell counts in the different studied populations: CW aged 40 and younger (purple), CW 40-60 years-old (red), CW older than 60 yearsold (orange), TW (green) and cis men (CM, black). Dashed line corresponds to the median among all measurements (CD4=657 cells/ μ L, CD8=715 cells/ μ L). For display purposes, 34 measurements (CD4>2500 cells/ μ L) and 77 measurements (CD8>3500 cells/ μ L) were excluded from the plot. Individual data points are shown in addition in Supplementary Figure 2.

374

Figure 3: Effect of sex hormone intake in CW<40 (purple), CW 40-60 (red), CW>60 (orange), and TW (green) on the scaled studied outcomes: CD4 counts, CD8 counts, CD4:CD8 ratio and lymphocytes counts. Models were adjusted for potential confounders such as years since first start of ART, ethnicity, intravenous drug use, education level, and age.

380

Figure 4: Effect of different type and route of hormones on immune markers: in green, comparison of TW taking oestrogens + androgens versus oestrogens only; in purple, comparison of CW<40 taking progestogens versus oestrogens+progestogens; in orange, comparison of CW>60 taking local oestrogens versus systemic oestrogen+progestogens. Models were adjusted for potential confounders such as years since first start of ART, ethnicity, intravenous drug use, education level, and age.

389 **Table 1:** Description of the population of cis women (CW) and trans women (TW) for

390 which samples were included in the analysis

	CW	TW	Overall		
Sample size	n=3092	n=83	n=3175		
Age in 2022:					
median (min,max)	53 (18,95)	45 (21,75)	53 (18,95)		
Ethnicity: n(%)					
White	1642 (53.1%)	36 (43.4%)	1678 (52.9%)		
Black	1103 (35.7%)	5 (6.0%)	1108 (34.9%)		
Hispano-american	104 (3.4%)	16 (19.3%)	120 (3.8%)		
Asian	227 (7.3%)	25 (30.1%)	252 (7.9%)		
Other/unknown	14 (0.5%)	1 (1.2%)	15 (0.5%)		
Missing	2 (0.1%)	0 (0%)	2 (0.1%)		
Education: n(%)					
Less than bachelor	2329 (75.3%)	63 (75.9%)	2392 (75.3%)		
Bachelor and more	635 (20.5%)	18 (21.7%)	653 (20.6%)		
Other/unknown	47 (1.5%)	2 (2.4%)	49 (1.5%)		
Missing	81 (2.6%)	0 (0%)	81 (2.6%)		
IVD use: n(%)					
No	2549 (82.4%)	80 (96.4%)	2629 (82.8%)		
Yes	518 (16.8%)	3 (3.6%)	521 (16.4%)		
Missing	25 (0.8%)	0 (0%)	25 (0.8%)		
Has taken sex hormones at					
least once since 2015: n(%)					
No	2509 (81.1%)	25 (30.1%)	2534 (79.8%)		
Yes	583 (18.9%)	58 (69.9%)	641 (20.2%)		

Table 2: Description of lab measurements (CD4, CD8, and lymphocyte counts, CD4:CD8 ratio, detectable viral load) from

393 the samples included in the statistical analysis. For each marker the number of measurements available (N) is displayed.

394

	CW	< 40	CW 4	10-60	CW > 60		TW		СМ
Under sex hormone	No	Yes	No	Yes	No	Yes	No	Yes	
Total sample size (N)	9730	1308	32030	3279	5786	618	637	753	147298
Age at sample time:	36 (32,38)	35 (30,38)	51 (46,55)	51 (45,55)	66 (63,71)	67 (62,76)	45 (38,52)	42 (37,50)	52 (44,59)
CD4 (cells/uL) (N)	8118	1108	27395	2805	5006	509	532	631	124823
median (Q1,Q3)	649 (480,861)	715 (557,954)	672 (488,887)	720 (548,929)	663 (477,878)	720 (580,893)	617 (426,892)	772 (520,1006)	651 (480,851)
CD8 (cells/uL) (N)	8064	1103	27194	2793	5001	494	531	616	123685
median (Q1,Q3)	674 (507,899)	656 (489,880)	675 (491,913)	651 (468,882)	656 (459,900)	557 (387,866)	755 (583,975)	822 (609,1033)	732 (534,996)
CD4:CD8 ratio (N)	8064	1103	27190	2793	5001	494	531	616	123679
median (Q1,Q3)	1.00 (0.70,1.35)	1.16 (0.81,1.54)	1.01 (0.71,1.39)	1.14 (0.82,1.59)	1.03 (0.67,1.50)	1.25 (0.92,1.76)	0.84 (0.56,1.12)	0.94 (0.69,1.22)	0.89 (0.62,1.24)
Lymphocytes (cells/uL) (N)	7974	1096	26670	2663	4812	487	525	618	121563
median (Q1,Q3)	1873 (1500,2332)	1908 (1529,2398)	1900 (1500,2400)	1937 (1569,2400)	1900 (1476,2395)	1870 (1558,2364)	2082 (1700,2581)	2288 (1768,2866)	1949 (1548,2421)
HIV-1 VL (copies/mL) (N)	9586	1288	31270	3212	5689	612	612	745	144228
Detectable VL (>50): n(%)	698 (7.2%)	45 (3.4%)	1499 (4.7%)	92 (2.9%)	256 (4.4%)	1 (0.2%)	53 (8.3%)	12 (1.6%)	6078 (4.1%)

Table 3: Description of sex hormones intake reported by women in the SHCS. Sex hormone reports are defined as explained in the supplementary figure 3. Total number

398 of sex hormone reports in each group are displayed (n).

- 399
- 400

		CW<40	CW 40-60	CW>60	TW
		n=390	n=620	n=76	n=158
	Systemic	13 (3.3%)	109 (17.6%)	8 (10.5%)	84 (53.2%)
Oestrogens	Local	8 (2.1%)	90 (14.5%)	48 (63.2%)	0
	Systemic & local	0	2 (0.3%)	2 (2.6%)	0
	Systemic	137 (35.1%)	131 (21.1%)	2 (2.6%)	4 (2.5%)
Progestogens	Local	55 (14.1%)	28 (4.5%)	0	0
	Systemic & local	3 (0.8%)	0	0	0
	Systemic	144 (36.9%)	238 (38.4%)	16 (21.1%)	2 (1.3%)
Oestrogens + Progestogens	Local	8 (2.1%)	3 (0.5%)	0	0
	Systemic & local	3 (0.8%)	7 (1.1%)	0	0
Antiandrogens	Systemic	0	1 (0.2%)	0	7 (4.4%)
Oestrogens + Antiandrogens	Systemic	17 (4.4%)	9 (1.5%)	0	52 (32.9%)
Oestrogens + Androgens	Systemic	0	2 (0.3%)	0	5 (3.2%)
Oestrogens + Antiandrogens + Androgens	Systemic	0	0	0	3 (1.9%)
Ostrogens + Progestogens + Antiandrogens	Systemic	2 (0.5%)	0	0	1 (0.6%)

402 **Acknowledgments.** We thank the participants of the SHCS, the physicians and study 403 nurses for excellent patient care, and the SHCS data center for excellent data 404 management.

405

406 Members of the Swiss HIV Cohort Study: Abela I, Aebi-Popp K, Anagnostopoulos A, 407 Battegay M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, 408 Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF 409 (President of the SHCS), Hachfeld A, Haerry D (deputy of "Positive Council"), Hasse B, 410 Hirsch HH, Hoffmann M, Hösli I, Huber M, Jackson-Perry D (patient representatives), 411 Kahlert CR (Chairman of the Mother & Child Substudy), Kaiser L, Keiser O, Klimkait T, 412 Kouyos RD, Kovari H, Kusejko K (Head of Data Centre), Labhardt N, Leuzinger K, 413 Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nemeth J, Nicca D, Notter J, 414 Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Salazar-415 Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory 416 Committee), Tarr P, Trkola A, Wandeler G, Weisser M, Yerly S.

417

Financial support. This work has been financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #201369), by SHCS project #882 and by the SHCS research foundation. The data were gathered by the 5 Swiss university hospitals, 2 cantonal hospitals, 15 affiliated hospitals, and 36 private physicians (listed at http://www.shcs.ch/180-health-care-providers). IAA is supported by a research grant of the Promedica Foundation. CP is supported by a Fellowship from the Collegium Helveticum.

425

426 **Potential conflicts of interests**.

IAA has received honoraria from MSD and Sanofi, a travel grant from Gilead Sciences, and a grant from the Promedica foundation. RDK has received research fundings from Gilead unrelated to this work. AH's institution has received travel grants, congress and advisory fees from MSD, Viiv and Gilead, unrelated to this work. KAP's institution has received travel grants and advisory fees from MSD, Gilead and ViiV healthcare unrelated to this work. HFG has received grants from the SNF; SHCS; Yvonne Jacob Foundation;

University of Zurich's Clinical Research Priority Program, viral disease; Zurich Primary
HIV Infection; Systems.X; National Institutes of Health; Gilead Sciences; and Roche; and
personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson

- and Novartis, for consultancy or DSMB membership and a travel grant from Gilead.
- 437

Authors contribution. CP, RDK: conception and design of the study, analysis and interpretation of data, drafting and revision of the article. IAA: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting and revision of the article. KAP: acquisition of data, analysis and interpretation of data, drafting and revision of the article. All other co-authors: acquisition of data, drafting and revision of the article.

444

445 Data availability. The individual level datasets generated or analyzed during the current
446 study do not fulfill the requirements for open data access:

1) The SHCS informed consent states that sharing data outside the SHCS network is only
permitted for specific studies on HIV infection and its complications, and to researchers
who have signed an agreement detailing the use of the data and biological samples; and
2) the data is too dense and comprehensive to preserve patient privacy in persons living
with HIV.

According to the Swiss law, data cannot be shared if data subjects have not agreed or data is too sensitive to share. Investigators with a request for selected data should send a proposal to the respective SHCS address (<u>www.shcs.ch/contact</u>). The provision of data will be considered by the Scientific Board of the SHCS and the study team and is subject to Swiss legal and ethical regulations, and is outlined in a material and data transfer agreement.

458

- 460 1. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males:
 461 implications for vaccine efficacy. Current opinion in physiology. 2018;6:16-20.
- 462 2. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the
 463 Outcomes of Vaccination over the Life Course. Annual Review of Cell and Developmental
 464 Biology. 2017;33(1):577-99.
- 465 3. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol.
 466 2016;16(10):626-38.
- 467 4. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines.
 468 Lancet Infect Dis. 2010;10(5):338-49.
- 469 5. Lotter H, Altfeld M. Sex differences in immunity. Semin Immunopathol. 2019;41(2):133470 5.
- 471 6. Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol. 2014;35(3):97-104.
- 472 7. Taneja V. Sex Hormones Determine Immune Response. Front Immunol. 2018;9:1931.
- 473 8. Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front474 Immunol. 2018;9:2279.
- 9. Ortona E, Pierdominici M, Rider V. Editorial: Sex Hormones and Gender Differences in
 Immune Responses. Frontiers in Immunology. 2019;10(1076).
- 477 10. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev
 478 Allergy Immunol. 2011;40(1):66-73.
- 479 11. Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiebaut R, Tibshirani RJ, Davis
- 480 MM. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in 481 the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869-74.
- 482 12. Rechtien A, Altfeld M. Sexual dimorphism in HIV-1 infection. Seminars in 483 Immunopathology. 2019;41(2):195-202.
- 13. Napravnik S, Poole C, Thomas JC, Eron JJ, Jr. Gender difference in HIV RNA levels: a
 meta-analysis of published studies. J Acquir Immune Defic Syndr. 2002;31(1):11-9.
- 486 14. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois
 487 ED, Feeney ME. Sex Differences in HIV RNA Level and CD4 Cell Percentage During Childhood.
 488 Clinical Infectious Diseases. 2011;53(6):592-9.
- 489 15. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial
 490 Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal
 491 of Medicine. 2001;344(10):720-5.
- 492 16. Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis. 493 2014;209 Suppl 3:S86-92.
- 494 17. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS,
 495 Shafer RW, Robbins GK, Pollard RB, Team A. Effect of Baseline- and Treatment-Related Factors
- 496 on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects:
- 497 Results From ACTG 384. JAIDS Journal of Acquired Immune Deficiency Syndromes.498 2006;42(4):426-34.
- 499 18. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ,
- 500 Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins
- 501 GK, Altfeld M. Sex differences in the Toll-like receptor-mediated response of plasmacytoid
- 502 dendritic cells to HIV-1. Nat Med. 2009;15(8):955-9.
- 503 19. El-Badry E, Macharia G, Claiborne D, Brooks K, Dilernia DA, Goepfert P, Kilembe W,
- 504 Allen S, Gilmour J, Hunter E. Better Viral Control despite Higher CD4+ T Cell Activation during

Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol. Journal of Virology. 2020;94(16):e00758-20.

- 507 20. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N,
- 508 Bogojeska J, Fellay J, Roth V, Kok YL, Thorball CW, Borghesi A, Parbhoo S, Wieser M, Boni J,
- 509 Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M,
- 510 Kouyos RD, Gunthard HF, Metzner KJ, the Swiss HIV Cohort Study. Determinants of HIV-1
- 511 reservoir size and long-term dynamics during suppressive ART. Nat Commun. 2019;10(1):3193.
- 512 21. Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A,
- 513 Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M,
- Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG. Sex-Based Differences in
 Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. The
 Journal of Infectious Diseases. 2018;219(7):1084-94.
- 517 22. Gianella S, Rawlings SA, Dobrowolski C, Nakazawa M, Chaillon A, Strain M, Layman L, 518 Caballero G, Scully E, Scott B, Pacis C, Weber KM, Landay A, Anderson C, Karn J. Sex
- 519 Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging.
- 520 Clinical Infectious Diseases. 2022;75(1):73-80.
- Das B, Dobrowolski C, Luttge B, Valadkhan S, Chomont N, Johnston R, Bacchetti P, Hoh
 R, Gandhi M, Deeks SG, Scully E, Karn J. Estrogen receptor-1 is a key regulator of HIV-1 latency
 that imparts gender-specific restrictions on the latent reservoir. Proc Natl Acad Sci U S A.
 2018;115(33):E7795-E804.
- 525 24. Scully EP. Sex Differences in HIV Infection. Current HIV/AIDS Reports. 2018;15(2):136526 46.
- Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, DelanyMoretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S,
 Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, WatsonJones D, van de Wijgert JH, Stalter R, Low N. Hormonal contraception and the risk of HIV
- 531 acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12(1):e1001778.
- 26. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk
 of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15(2):181-9.
 27. Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal
- 534 27. Cuttis KW, Halmalold FC, Rodriguez WI, Chipato F, Steyn FS, Klane JN. Hormonal
 535 contraception and HIV acquisition among women: an updated systematic review. BMJ Sexual &
 536 Reproductive Health. 2020;46(1):8-16.
- 537 28. Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D, Gichangi PB,
- 538 Heller KB, Hofmeyr GJ, Justman J, Kasaro MP, Kiarie J, Louw C, Mastro TD, Morrison CS,
- 539 Mugo NR, Nair G, Nanda K, Nhlabatsi Z, Onono M, Palanee-Phillips T, Pleaner M, Rees H,
- 540 Singata-Madliki M, Scoville CW, Selepe RAP, Shears K, Sibiya S, Smit J, Steyn PS, Stringer J,
- 541 Taylor D, Thomas KK, Welch JD. HIV incidence among women using intramuscular depot
- 542 medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for
- 543 contraception: a randomised, multicentre, open-label trial. The Lancet. 2019;394(10195):303-13.
- 544 29. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV
 545 disease progression: a systematic review. AIDS. 2013;27(5):787-94.
- 546 30. Whiteman MK, Jeng G, Samarina A, Akatova N, Martirosyan M, Kissin DM, Curtis KM, 547 Marchbanks PA, Hillis SD, Mandel MG, Jamieson DJ. Associations of hormonal contraceptive
- 548 use with measures of HIV disease progression and antiretroviral therapy effectiveness.
- 549 Contraception. 2016;93(1):17-24.

550 31. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden

of HIV in transgender women: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2013;13(3):214-22.

- 32. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global Epidemiology of HIV Infection
 and Related Syndemics Affecting Transgender People. JAIDS Journal of Acquired Immune
 Deficiency Syndromes. 2016;72.
- 556 33. Nguyen H, Hampel B, Garcia Nuñez D, Battegay M, Hachfeld A, Bernasconi E, Calmy A,
- 557 Cavassini M, Vernazza P, Fellay J, Rudolph H, Huber M, Leuzinger K, Perreau M, Scherrer A,
- Ramette AN, Yerly S, Günthard HF, Kouyos RD, Kusejko K, the Swiss HIV Cohort Study.
 Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an
 Epidemiologically Distinct Risk Group. Clinical Infectious Diseases. 2021.
- 561 34. Stahlman S, Liestman B, Ketende S, Kouanda S, Ky-Zerbo O, Lougue M, Diouf D, Anato 562 S, Tchalla J, Bamba A, Drame FM, Ezouatchi R, Kouamé A, Baral SD. Characterizing the HIV 563 risks and potential pathways to HIV infection among transgender women in Côte d'Ivoire, Togo 564 and Burkina Faso. Journal of the International AIDS Society. 2016;19(3S2):20774.
- Gianella S, Sonya Haw J, Blumenthal J, Sullivan B, Smith D. The Importance of Human
 Immunodeficiency Virus Research for Transgender and Gender-Nonbinary Individuals. Clin
 Infect Dis. 2018;66(9):1460-6.
- 568 36. Jaspal R, Kennedy L, Tariq S. Human Immunodeficiency Virus and Trans Women: A 569 Literature Review. Transgend Health. 2018;3(1):239-50.
- 570 37. Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV 571 treatment: a comprehensive review of the literature and recommendations for best practices. J Int 572 AIDS Soc. 2016;19(3 Suppl 2):20810.
- 573 38. Wansom T, Guadamuz TE, Vasan S. Transgender populations and HIV: unique risks, 574 challenges and opportunities. J Virus Erad. 2016;2(2):87-93.
- 575 39. Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, Lake JE.
- Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing
 Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns. LGBT

Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns. LGBT
 Health. 2017;4(5):371-5.

- 40. Murray MM, Jensen A, Cieslik T, Cohn SE. Potential risk of drug-drug interactions with
 hormonal contraceptives and antiretrovirals: prevalence in women living with HIV. Drugs Context.
 2020;9.
- 582 41. Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent Tobacco Smoking is Associated with
- 583 Poor HIV Medical Outcomes Among HIV-Infected Individuals in New York. AIDS and Behavior.

584 2016;20(8):1722-9.

- Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, Gandhi M,
 Mocharnuk RS, Anastos K. Association of Cigarette Smoking With HIV Prognosis Among
 Women in the HAART Era: A Report From the Women's Interagency HIV Study. American
 Journal of Public Health. 2006;96(6):1060-5.
- 589 43. Muccini C, Crowell TA, Pinyakorn S, Kroon E, Sacdalan C, Ananworanich J, Vasan S,
- 590 Phanuphak N, Colby DJ. Brief Report: Syphilis Incidence and Effect on Viral Load, CD4, and
- 591 CD4/CD8 Ratio in a Thai Cohort of Predominantly Men Who Have Sex With Men Living With
- 592 HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2021;86(2).
- 593 44. Giltay EJ, Fonk JCM, von Blomberg BME, Drexhage HA, Schalkwijk C, Gooren LJG. In
- 594 Vivo Effects of Sex Steroids on Lymphocyte Responsiveness and Immunoglobulin Levels in
- 595 Humans. The Journal of Clinical Endocrinology & Metabolism. 2000;85(4):1648-57.

596 45. Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr Philip E, Darling K, Babouee Flury B,

- Polli C, Sultan-Beyer L, Abela IA, Aebi-Popp K, the Swiss HIV Cohort Study. Women with HIV
 transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). HIV
 Medicine. 2022;23(4):417-25.
- 600 46. Peckham H, Webb K, Rosser EC, Butler G, Ciurtin C. Gender-Diverse Inclusion in 601 Immunological Research: Benefits to Science and Health. Front Med 2022;9:909789.
- 602 47. Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21603 9.
- 48. Pulendran B. Systems vaccinology: Probing humanity's diverse immune systems with
 vaccines. Proceedings of the National Academy of Sciences. 2014;111(34):12300.
- 606 49. Lacombe-Duncan A, Bauer GR, Logie CH, Newman PA, Shokoohi M, Kay ES, Persad Y,
- O'Brien N, Kaida A, de Pokomandy A, Loutfy M. The HIV Care Cascade Among Transgender
 Women with HIV in Canada: A Mixed-Methods Study. AIDS Patient Care and STDs.
 2019;33(7):308-22.
- 610 50. Jäggi T, Jellestad L, Corbisiero S, Schaefer DJ, Jenewein J, Schneeberger A, Kuhn A, 611 Garcia Nuñez D. Gender Minority Stress and Depressive Symptoms in Transitioned Swiss
- 612 Transpersons. BioMed Research International. 2018;2018:8639263.
- 51. Baker KE, Wilson LM, Sharma R, Dukhanin V, McArthur K, Robinson KA. Hormone
 Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review.
 Journal of the Endocrine Society. 2021;5(4):bvab011.
- 52. Hughto JMW, Gunn HA, Rood BA, Pantalone DW. Social and Medical Gender
 Affirmation Experiences Are Inversely Associated with Mental Health Problems in a U.S. NonProbability Sample of Transgender Adults. Archives of Sexual Behavior. 2020;49(7):2635-47.
- 619 53. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B,
 620 Bernasconi E, Rickenbach M, Günthard HF, Bucher HC, the Swiss HIV Cohort Study.
- 621 Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to 622 Antiretroviral Therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency
- Antiretroviral Therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency
 Syndromes. 2010;54(2).
- 54. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV Infected
 Patients: a Review. Current Psychiatry Reports. 2014;17(1):530.
- 626 55. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and
 627 HIV/AIDS: the need for an integrated response. AIDS. 2019;33(9).
- 628 56. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and Adherence to
- Antiretroviral Therapy in Low-, Middle- and High-Income Countries: A Systematic Review and
 Meta-Analysis. Current HIV/AIDS Reports. 2014;11(3):291-307.
- 631 57. de Wit AE, Booij SH, Giltay EJ, Joffe H, Schoevers RA, Oldehinkel AJ. Association of
- Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women.
 JAMA Psychiatry. 2020;77(1):52-9.
- 634 58. Kulkarni J. Depression as a side effect of the contraceptive pill. Expert Opinion on Drug
 635 Safety. 2007;6(4):371-4.
- 636 59. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal
 637 Contraception With Depression. JAMA Psychiatry. 2016;73(11):1154-62.
- 638 60. Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr PE, Darling KEA, Babouee Flury B, Polli
- 639 C, Sultan-Beyer L, Abela IA, Aebi-Popp K, the Swiss HIV Cohort Study. Brief Report: Does
- 640 Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?
- 541 JAIDS Journal of Acquired Immune Deficiency Syndromes. 2023;92(5):399-404.

- 642 61. Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen 643 therapy on circulating inflammatory markers. Maturitas. 2009;62(3):281-6.
- 644 62. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, Furrer H, Schmid
- 645 P, Bernasconi E, Stoeckle M, Kahlert C, Trkola A, Kouyos RD, Tarr P, Marzolini C, Wandeler G,
- 646 Fellay J, Bucher H, Yerly S, Suter F, Hirsch H, Huber M, Dollenmaier G, Perreau M, Martinetti
- 647 G, Rauch A, Günthard HF. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). Int J
- 648 Epidemiol. 2022;51(1):33-4j.
- 649 63. Olink Inflammation 2019 [Available from:
- 650 <u>https://www.olink.com/content/uploads/2019/04/Olink-Inflammation-Validation-Data-v3.0.pdf</u>.
- 651






Figure 2





TW: oestrogens+androgens vs oestrogens only

Marker medRxiv preplininger: regression goefficient [95%6.1]9.23289654; this version posted/why regreger: The cost of the set of the

